Jinwei (http://www.jinweibio.com/en/) is a biotechnology company working in partnership with Theravectys –France, a spin-off of Pasteur institute. Our platform is based on a state-of art patented Lentiviral vector technology.
Jinwei’s goal is to develop customized lentiviral vectors services to meet the requirements of an increasingly demanding healthcare market. As a biotechnology company, we develop non-CAR-T based therapeutic vaccines for patients suffering from cancer and other major infectious diseases. We also deliver safe and reliable viral vector system for CAR-T cell therapy application as a contract manufacturer.
Jinwei’s ambition is to have a highly engaged scientific team with top scientists who are inspired to take project ownership and further develop themselves in one of the most rapidly growing scientific fields.
The R&D Lab Manager will be based in Shanghai ZhangJiang Hi-Tech Park. The manager of R&D Lab will lead implementation of GLP and lead a small group of scientists and technicians to implement the protocols for proof of the concept in new indications and to ensure good quality of experiments through collaborations with third party service providers.